Thus, given the modest activity of the FDA-approved SMO inhibitors against xenografts of human T-ALL and the known issue of emergence of resistance to these drugs in other cancer clinical trials, it will be imperative to determine which signaling pathways alter sensitivity to HH pathway inhibitors. This evidence concerns the gene SMO and cancer.